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Although mouse models have represented a major tool 
for understanding and predicting molecular mechanisms 
responsible for several human genetic diseases, still species-
specific differences between mouse and humans in their 
biochemical and physiological characteristics represent a 
major hurdle when translating promising findings into the 
human setting (1). For instance, in several types of maturity 
onset diabetes of the young (MODY; autosomal dominant), 
mice with heterozygous mutations do not develop 
diabetes (2). In this regard, the derivation of human 
embryonic stem cells (hESCs) in 1998 represented an 
unprecedented opportunity for human disease modelling, 
and a promising source for cell replacement therapies (3). 
Later on, the possibility to generate patient-derived induced 
pluripotent stem cells (iPSCs) has opened new venues for 
the potential translation of stem-cell related studies into the 
clinic (4). 
Diabetes is one of the most common metabolic disorders 
worldwide, and a major cause of mortality and morbidity 
for which a cure remains elusive. Since the absence of 
functional insulin-secreting pancreatic β-cells results in 
diabetes, the possibility to generate functional β-cells from 
human pluripotent stem cells (hPSCs) has represented a 
major challenge in the field. Contrary to other prevalent 
disorders requiring different cell types in order to restore 
the loss of function in the damaged tissue (i.e., heart), 
β-cells derived from hPSCs would represent the only cell 
type missing in diabetes that could further be transplanted 
in non-endogenous sites, thus, representing a promising 
treatment for type 1 diabetics in the future (5). 
Recent insights into β-cells derivation from hPSCs 
have contributed to the identification of transcriptional 
regulators and cell culture conditions converting terminally 
differentiated cells into β-cells, and even to define novel 
conditions sustaining β-cells replication in vitro and in vivo 
(6-8). Although these findings are encouraging, still the 
developmental mechanisms responsible of early and later 
stages of β-cell differentiation remain unclear. In addition, 
and more importantly, how these processes interfere in the 
acquisition of functional capabilities of β-cells after birth is 
still unknown.
In the work by Zhu et al. (9), the authors are able 
to examine these relevant questions in a controlled 
and unbiased manner. To this end, they systematically 
analyze the role of pancreatic lineage determinants in 
differentiation and disease making use of genome editing 
technology in hPSCs. In order to establish a cellular system 
for the interrogation of the putative role of specific factors 
with a known role in pancreas development in the murine 
system, the authors first generated a cellular platform for 
inducible gene expression for gain of function analysis 
in hESCs. For this purpose, the authors simultaneously 
integrated a constitutive promoter driving the expression 
of an optimized form of reverse tetracycline-controlled 
transactivator (M2rtTA), and a tetracycline-response 
element (TRE) driving the expression of the gene of interest 
(NotchIC and NGN3) in the AAVS1 transgene safe harbor 
locus in the hESCs-HUES8 line by TALENs mediated 
gene editing. Next, in order to model human pancreatic 
development, the authors adapted an existing protocol 
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for direct pancreatic differentiation from hPSCs (10) 
and proceeded to characterize the different pancreatic 
populations emerged during the onset of differentiation 
using untargeted HUES8-hESCs. By this approach Zhu 
et al. derived definitive endoderm (DE) cells (expressing 
SOX17 and FOXA2); pancreatic progenitors (PP) expressing 
PDX1 (PDX1+); and polyhormonal β-cells (PH-β) 
expressing endocrine hormones characteristic of β and α 
cells. This model allowed the further analysis on the effect 
of NGN3 and NOTCH perturbation in HUES8-hESC 
transgenic lines by the inducible expression of NGN3 
(iNGN3) and NotchIC (iNothIC), revealing a conserved 
role of these factors between human and murine systems in 
pancreatic differentiation.
Next the authors interrogated the specific role of eight 
pancreatic transcription factors (PDX1, RFX6, PITF1A, 
GLIS3, MNX1, NGN3, HES1 and ARX) by combining 
TALEN and CRISPR/Cas-mediated gene editing in 
hPSCs. Six out of the eight factors are associated with 
permanent neonatal diabetes mellitus (PNDM), and biallelic 
inactivation of these genes is thought to be responsible for 
the absence of pancreatic endocrine cells in patients (PDX1, 
RFX6, PITF1A, GLIS3, MNX1, NGN3) (11-16). Similarly, 
mutations in both PDX1 and PITF1A were previously 
associated with pancreatic agenesis. In order to generate a 
massive platform allowing loss-of-function studies for the 
examination of the selected factors’ role, the authors used 
a previously developed gene editing platform in hPSCs 
allowing doxycycline-regulated expression of the RNA-
guided DNA endonuclease Cas9 (17). Using this system, 
simple transfection of synthetic chimeric guide RNAs 
(gRNAs) in doxycycline-treated hPSCs, allowed efficient 
generation of mutant hPSCs lines (17). In the current work, 
the authors increased the throughput of their platform 
designing two distinct gRNAs for each gene of interest that 
were synthesized in a compatible multi-well format, thus 
minimizing potential CRISPR/Cas9 off-target effects. In 
this manner, they were able to generate either biallelic “−/−” 
or monoallelic “−/+” knockout alleles carrying frameshift 
mutations. Of note, none of the studied mutations had an 
impact in the formation of DE. On the contrary, at the PP 
stage, RFX6−/− mutants showed a ~40% reduction of PDX1+ 
cells that was unrelated to a reduction in proliferation or 
an increase in apoptosis. Based on these findings, Zhu’s 
conclusions were that RFX6 regulates PDX1 expression in 
a direct or indirect manner, and that the absence of RFX6 
impairs the formation of PP cells. These results were in 
agreement with previous observations in Rfx6−/− mice (15) 
and patients carrying biallelic mutations in RFX6 (18), 
leading the authors to speculate that similar phenotype 
should be present during mice development. 
Moreover,  when the  authors  ana lyze  PDX1 +/− 
mutants they observed a reduction in the number 
of pancreatic endocrine cells expressing insulin and 
glucagon (characteristic of β and α cells, respectively). In 
order to prove that the observed phenotypes were due 
to haploinsufficiency and not to a possible dominant-
negative effect, they derived biallelic mutant lines carrying 
the same mutations of the two heterozygous lines (either 
PDX1L36fs/L36fs or PDX1L36fs/L34fs). Zhu et al. observed that 
no PDX1+ were derived in biallelic mutant lines, thus 
confirming that losing one functional PDX1 allele impairs 
pancreatic differentiation. These findings together with 
the fact that there is a clear association between PDX1 
heterozygous mutations and genetic variants to type 2 
diabetes (2,19,20) led the authors to conclude that defects in 
β cell development may predispose to diabetes. 
Following with their systematic and accurate analysis, 
the authors also found out that contrary to Ngn3−/− mutant 
mice, where no INS+ cells are detected during the onset 
of pancreatic development, NGN3−/− hESC lines still gave 
rise to a small percentage of insulin positive cells (INS+). 
Since a small fraction of patients diagnosed with permanent 
or transient neonatal diabetes carrying biallelic NGN3 
mutations also displayed low levels of blood C-peptide 
(12,21), the authors suggested that in NGN3−/− hESCs lines, 
β cells could still be formed in the absence of any NGN3 
activity. In order to test this hypothesis, they generated 
another battery of NGN3 mutants (NGN3 null mutants 
and NGN3 disease-mimicking lines) that were INS+ at the 
PH-β stage. These observations were in agreement with 
findings in NGN-deficient patients that displayed C-peptide 
levels besides disease-associated symptoms. These 
findings lead the authors to interrogate until which extent 
NGN3−/− derived cells could give rise to mature β cells. 
To this end, Zhu et al. engineered 2 additional lines on the 
NGN3−/− background through homology-directed repair 
(HDR) using a single-stranded DNA donor (NGN3Cr/Cr 
lines). Then, NGN3Cr/Cr lines together with wild type 
counterparts were further differentiated to insulin secreting 
cells (β-like cells) following a previously reported protocol 
(5,22). By this elegant approach, the authors unambiguously 
showed that β-like cells derived from NGN3−/− lines that 
were positive for C-peptide expression (CPEP+; ~0.5%) did 
not co-express glucagon neither somatostatin, but NKX6.1 
(~0.05% from the total population). Moreover, β-like 
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cells derived from NGN3−/− lines did not exhibit glucose-
stimulated insulin secretion. All these results led the authors 
to conclude that NGN3 is not absolutely required for 
the formation of monohormonal CPEP+, but may lead 
to impaired β cell function in NGN3-deficient patients. 
Lastly, in order to determine the developmental window 
for NGN3 activity during human pancreas formation, 
the authors also generated inducible NGN3 lines in the 
NGN3−/− hESC background by replacing the Puro-iCas9 
cassette targeted in the AAVS1 locus with an hygro-iNGN3 
transgene through HDR. In their hands, the expression of 
NGN3 transgene gave rise to the generation of endocrine 
cells at all the evaluated stages, with major effects on the 
generation of both PDX1+/NKX6.1− and PDX1+/NKX6.1+ 
β-cells. 
Overall, the work led by Dr. Huangfu demonstrates 
the power of genome editing combined with hPSCs 
technology in order to systematically explore the role of 
a large number of candidate genes previously related with 
PNDM and pancreatic development in the human setting. 
Expanding the potential of their cellular platform by the 
generation of multiple cell lines by HDR, the authors 
developed a large number of mutant hPSCs in a short time 
period validating the observed cellular phenotypes at the 
mechanistic level. Importantly, the authors were also able 
to identify previously unknown effects when mutating 
pancreatic transcription factors related with PDNM, as 
RFX6, identified in this work as a key factor necessary 
for both early formation of PP and the development of 
functional endocrine cells. Overall, Zhu et al. are to be 
congratulated for adding a comprehensive view about 
genome editing possibilities when modeling human 
differentiation and disease. This work highlights the use of 
this powerful cellular toolbox for the validation of in vivo 
studies avoiding confounding effects related to the 
limitations of murine models or other issues related with the 
use of patient derived iPSCs for disease modeling (i.e., need 
of primary patient samples, differences in differentiation 
efficiencies, among others) (23).
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